Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gentian Diagnostics AS (GENT.OL)
Moss, NO
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.27% | -4.51% | -10.14% | -2.81% | -32.92% | -33.39% | -32.45% | -18.59% | -20.63% | +46.54% | +46.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+16.1% ★ Q2'26: +14.2% (vs Q2'25)
-
EPS growth Medical - Specialties: +10.1%-70.0% Q2'26: +323.1% (vs Q2'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+4.3% Q2'26: -6.6% (vs Q2'25)
-
EBIT margin Medical - Specialties: +12.6%+11.7% Q2'26: +15.1% (vs Q2'25)
-
ROIC Medical - Specialties: +6.6%+10.2% ★ Q2'26: +16.5% (vs Q2'25)
-
Share dilution Medical - Specialties: 0.0%-1.7% ★ Q2'26: +0.2% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.77× ★ Q2'26: 0.43× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
34.99M
est: 27.50M (+27.2%)
|
46.11M
est: 35.70M (+29.2%)
|
47.95M
est: 52.20M (-8.1%)
|
68.37M
est: 78.88M (-13.3%)
|
83.12M
est: 102.99M (-19.3%)
|
101.64M
est: 111.56M (-8.9%)
|
136.19M
est: 141.87M (-4.0%)
|
152.07M
est: 151.23M (+0.6%)
|
176.50M
est: 182.00M (-3.0%)
|
200.00M
200.00M – 200.00M
+9.9% YoY
|
238.00M
238.00M – 238.00M
+19.0% YoY
|
265.00M
265.00M – 265.00M
+11.3% YoY
|
| EBITDA |
-12.10M
est: -2.07M (-484.6%)
|
-15.77M
est: -2.69M (-487.0%)
|
-21.02M
est: -3.93M (-435.0%)
|
-12.52M
est: -5.94M (-110.9%)
|
-18.38M
est: -7.75M (-137.1%)
|
-15.94M
est: -8.40M (-89.8%)
|
-3.08M
est: -10.68M (+71.1%)
|
31.54M
est: 80.43M (-60.8%)
|
29.82M
est: 96.80M (-69.2%)
|
106.37M
106.37M – 106.37M
+9.9% YoY
|
126.58M
126.58M – 126.58M
+19.0% YoY
|
140.94M
140.94M – 140.94M
+11.3% YoY
|
| EBIT |
-15.12M
est: -3.68M (-310.8%)
|
-19.67M
est: -4.78M (-311.5%)
|
-27.15M
est: -6.99M (-288.5%)
|
-16.92M
est: -10.56M (-60.2%)
|
-23.41M
est: -13.79M (-69.8%)
|
-22.36M
est: -14.94M (-49.7%)
|
-9.57M
est: -19.00M (+49.6%)
|
22.58M
est: 74.35M (-69.6%)
|
20.70M
est: 89.48M (-76.9%)
|
98.33M
98.33M – 98.33M
+9.9% YoY
|
117.01M
117.01M – 117.01M
+19.0% YoY
|
130.28M
130.28M – 130.28M
+11.3% YoY
|
| Net Income |
-15.17M
est: -20.65M (+26.5%)
|
-19.80M
est: -15.13M (-30.8%)
|
-39.86M
est: -39.25M (-1.6%)
|
-17.11M
est: -17.86M (+4.2%)
|
-24.79M
est: -13.73M (-80.5%)
|
-24.00M
est: -24.79M (+3.2%)
|
-10.65M
est: -3.54M (-200.9%)
|
45.29M
est: 15.63M (+189.9%)
|
13.26M
est: 15.95M (-16.9%)
|
22.61M
22.61M – 22.61M
+41.7% YoY
|
39.96M
39.96M – 39.96M
+76.7% YoY
|
48.79M
48.79M – 48.79M
+22.1% YoY
|
| SGA |
832.0K
est: 4.15M (-80.0%)
|
19.83M
est: 5.39M (+267.7%)
|
2.01M
est: 7.88M (-74.5%)
|
2.09M
est: 11.91M (-82.5%)
|
1.70M
est: 15.56M (-89.1%)
|
2.39M
est: 16.85M (-85.8%)
|
48.12M
est: 21.43M (+124.5%)
|
49.78M
est: 31.23M (+59.4%)
|
54.33M
est: 37.58M (+44.6%)
|
41.30M
41.30M – 41.30M
+9.9% YoY
|
49.15M
49.15M – 49.15M
+19.0% YoY
|
54.72M
54.72M – 54.72M
+11.3% YoY
|
| EPS |
-1.08
est: -1.31 (+17.6%)
|
-1.29
est: -0.96 (-34.4%)
|
-2.59
est: -2.49 (-4.0%)
|
-1.11
est: -1.13 (+2.1%)
|
-1.61
est: -0.87 (-84.8%)
|
-1.56
est: -1.57 (+0.8%)
|
-0.69
est: -0.22 (-207.3%)
|
2.94
est: 1.01 (+191.4%)
|
0.86
est: 1.03 (-16.5%)
|
1.46
1.46 – 1.46
+41.7% YoY
|
2.58
2.58 – 2.58
+76.7% YoY
|
3.15
3.15 – 3.15
+22.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matti Heinonen | Chief Executive Officer | 5M | male |
| Markus Jaquemar | Chief Growth Officer | 3M | male |
| Njaal Kind | Chief Financial Officer & Chief Operating Officer | 2M | male |
| Aleksandra Havelka | Chief Scientific Officer | 2M | — |
| Frank Frantzen | Chief Technology Officer | 2M | male |
| Tom Nilsen | Head of Product Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GENT.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
